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Abstract 
Review on +X solely in acute lymphoblastic 
leukemia, with data on clinics. 
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Figure 1.  Fluorescence in situ hybridization with centromeric CEP X/Y probe (Abbott Molecular, Vysis, US) 
showing 2 copies of chromosome X (green signal) on metaphase and interphase cells. Partial karyotype showing 
an extra copy of chromosome X (inset). 
Clinics and pathology Disease 
Acute lymphoblastic leukemia (ALL), virtually all 
cases display a B-cell phenotype (except 1 T-cell 
ALL described by Heerema et al., 1998). 
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Epidemiology 
34 patients (17 males and 17 females) aged 1 to 67 
years (median 6 years); among them 17 patients were 
pediatric cases aged 1 to 16 years (median 4  
 
years) (Privitera et al., 1992; Dastugue et al., 1992 ; 
Pui et al., 1993; Kempski et al., 1997; Heinonen et 
al., 1999; Silva et al., 2002; Chan et al., 2003; 
Kristensen et al., 2003; Russell et al., 2009; Lundin 
et al., 2014; Olsson et al., 2015; Liu et al., 2016). Up 
to half of these patients were Down syndrome (DS) 
cases (n=16)  aged 1 to 13 years (Kalwinsky et al., 
1990; Dastugue et al., 1992 ; Pui et al., 1993; 
Kempski et al., 1997; Heinonen et al., 1999; 
Mullighan et al., 2009; 2009; Russell et al., 2009; 
Lundin et al., 2014;). Adult patients were 20 to 59 
years old (median 38 years) (from the known data) 
(Fuscaldo et al., 1981; Foa et al., 2003; Yamamoto 
et al., 2004; Chapiro et al., 2010; Eyre et al., 2012; 
Safavi et al., 2015; Yasuda et al., 2016) (Table 1). 
 
Table 1. Clinical and karyotypic data of ALL 





1  F/59 47,XX,+X 
2 M 48,XY,+X,+21c 
3 F/4 48,XX,+X,+21c 
4 M/7  47,XY,+X/47,idem,add(11)(p15) 
5 M/2  48,XY,+X,+21c 
6 F/4 48,XX,+X,+21c 
7 M 46,XY,+X,inv(9)c      at relapse  
8 F/3  48,XX,+X,+21c 
9 M  47,XY,+X 
10 F/3  48,XX,+X,+21c 
11 F/16  
47,XX,+X/47,idem,i(17)(q10)/47,idem,dup(
1)(q21q32) 
12 F/16  47,XX,+X 
13 M/21  
48,XY,del(1)(p22),t(1;19)(q23p13),+mar/4
7,XY,+X 
14 F/6  47,XX,+X 
15 F/53  47,XX,+X      at relapse 
16 M  
48,XY,+X,+21c      PAR1 deletion, P2RY8-
CRLF2 by RT-PCR 
17 M  48,XY,+X,+21c 
18 F  48,XX,+X,+21c  
19 F  48,XX,+X,+21c/48,idem,i(17)(q10) 
20 M  48,XY,+X,+21c 
21 M  48,XY,+X,+21c 
22 M  47,XY,+X 
23 M/4  48,XY,+X,+21c/49,idem,+17 
24 F/5  48,XX,+X,+21c 
25 F/3  47,XX,+X 
26 F/8  47,XX,+X 
27 F/38  47,XX,+X 
28 M/22  
47,XY,+X      episomal amplification of 
NUP214-ABL1 
29 M/13 48,XY,+X,+21c  
30 M/1 48,XY,+X,+21c 
31 F/2B 47,XX,+X 
32 M/41 47,XY,+X 
33 F/4  47,XX,+X 
34 M/20  47,XY,+X 
Abbreviations: M, male; F, female 
1. Fuscaldo et al., 1981; 2. Kalwinsky et al.,  1990; 
3. Dastugue et al., 1992; 4. Privitera et al., 1992; 5-6 
Pui et al., 1993;  7. Chucrallah et al., 1995; 8. 
Kempski et al., 1997; 9. Heerema et al., 1998; 10.  
Heinonen et al., 1999; 11. Silva et al., 2002; 12. Chan 
et al., 2003; 13. Foa  et al., 2003; 14. Kristensen et 
al., 2003; 15. Yamamoto et al., 2004; 16-22.  
Mullighan et al., 2009; 23-26. Russell et al., 2009; 
27. Chapiro et al., 2010; 28.  Eyre et al., 2012; 29-
30. Lundin et al., 2014; 31. Olsson et al., 2015; 32.  
Safavi et al., 2015; 33. Liu et al., 2016; 34. Yasuda 
et al ., 2016. 
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Prognosis 
+X as the sole anomaly may have not affect the 
prognosis in ALL patients and likely should be 
considered an indicator of low risk factor (Dastugue 
et al., 1992). 
Cytogenetics 
Additional anomalies 
Out of 34 patients, the extra chromosome X was 
observed in a sideline in 5: in association with 
add(11)(p15) in 1 (Privitera et al., 1992), i(17)(q10) 
/ dup(1)(q21q32) in 1 (Silva et al., 2002), 
del(1)(p22), t(1;19)(q23p13) in 1 (Foa et al., 2003), 
i(17)(q10) in 1 DS (Mullighan et al., 2009) and  +17 
in other DS patient (Russell et al., 2009). 




X-chromosome aneuploidy is a known numerical 
anomaly in ALL, especially in childhood ALL where 
it can be detected in nearly all children with a high 
hyperdiploid karyotype (Heinonen et al., 1999). It is 
also the most common acquired changes in DS-ALL 
were it is observed in between 25% and 50% of 
patients (Pui et al 1993). However, the acquired gain 
of an X chromosome as a sole abnormality has been 
observed only in a relatively small number of ALL 
patients. Notably, up to half of the  cases were 
described in pediatric patients with Down syndrome, 
indicating that combination of  trisomy 21 and +X 
chromosome seems to be typical of DS-ALL that and 
may lead to collaboration of genes on chromosomes 
21 and X (Malinge et al., 2009). The result of 
chromosome X gain is an increased gene dosage that 
alters expression of many genes at the same time 
some of which could promote oncogenesis. In 
addition to an increased dosage of genes on 
chromosome X, recurring cryptic anomalies such as 
interstitial deletion of Xp22.33/Yp11.32 that 
juxtaposes the first, noncoding exon of P2RY8 
(pseudoautosomal region 1 of chromosomes X and 
Y) with the coding region of CRLF2 (cytokine 
receptor-like factor 2) or translocations t(X;14) 
between these regions and the immunoglobulin 
heavy chain locus at 14q32.33 may contribute to 
leukemogenesis in B-cell acute lymphoblastic 
leukemia (Mullighan 2009; Russell et al., 2009). 
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